MCL Literature Feed

A rare case of MCL presenting as diffuse polyposis throughout the entire GI tract achieved complete response after R-CHOP followed by salvage chemotherapy plus ibrutinib, highlighting this unusual presentation.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This case report details a rare MCL presentation as intestinal intussusception, requiring surgical resection for diagnosis and initial management prior to systemic chemotherapy in a young patient.

This case report identifies life-threatening aplastic anemia as a rare but fatal toxicity of acalabrutinib in MCL, urging clinicians to consider it in patients developing pancytopenia.

This study analyzes molecular responses in exceptional responders to the BTKi tirabrutinib, aiming to identify biomarkers for deep, durable remissions in relapsed/refractory mantle cell lymphoma.

This paper outlines the diagnostic and treatment challenges of rare ocular and nasopharyngeal MCL, highlighting the necessity of a multidisciplinary approach for managing these extranodal presentations.

This review summarizes how molecular profiling (e.g., TP53) and MRD are reshaping MCL therapy by integrating novel agents into frontline care, personalizing treatment, and improving high-risk patient outcomes.

This meta-analysis of phase 2/3 trials quantifies venous thromboembolism risk after CAR-T therapy, providing crucial data to guide thromboprophylaxis strategies in MCL patients.

This review explains MCL's clinical heterogeneity through distinct molecular subtypes and genomic alterations like TP53, which serve as key prognostic biomarkers and guide development of novel therapies.

Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.

For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.

This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.

This case report describes a rare presentation of MCL with paraneoplastic membranous nephropathy, highlighting the need to consider MCL in the differential diagnosis of unexplained nephrotic syndrome.

This multicenter retrospective study analyzes real-world maintenance strategies in mantle cell lymphoma, providing evidence to guide treatment selection and duration after initial therapy.

Preclinical data show WEE1 inhibition synergizes with bortezomib by inducing mitotic pyroptosis, a novel cell death mechanism, suggesting a potential strategy to overcome proteasome inhibitor resistance in MCL.

This study of Burkitt Lymphoma reveals the key MCL oncogene SOX11 has a context-dependent function, with a transcriptional program and downstream effects differing from its established role in MCL.

This paper identifies a subset of MCL with IRTA1-positive reactive marginal zone expansion, highlighting a potential diagnostic pitfall for pathologists distinguishing it from marginal zone lymphoma.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

Preclinical data show combining a BCL-XL inhibitor with venetoclax overcomes resistance in MCL models, even in BIM-deficient cells, suggesting a new strategy for venetoclax-refractory patients.

This review highlights BTK's non-catalytic scaffolding function as a novel mechanism of BTKi resistance, presenting a new therapeutic target beyond kinase inhibition for treating B-cell lymphomas like MCL.

BTK inhibition suppresses key metabolic pathways, allowing non-invasive imaging of metabolites like lactate and alanine as early, sensitive biomarkers of therapeutic response in MCL patients.

A computational, network-based analysis of MCL transcriptomic data identified novel progression pathways, highlighting VEGFA and SPARC as potential drug targets and providing a framework for drug repurposing.

This case report describes a novel nodular endoscopic presentation of primary nasopharyngeal MCL, expanding the differential diagnosis for nodular lesions in this rare location beyond benign or infectious causes.

This case report of an 80-year-old woman with laryngeal MCL highlights a rare extranodal presentation, underscoring the need to consider lymphoma in the differential for persistent throat symptoms.

CD20-targeted CAR-T therapy induced durable remissions (>7 years) in MCL by triggering a lasting endogenous anti-tumor immune response (epitope spreading) despite a lack of CAR-T persistence.

This paper likely provides a retrospective or real-world analysis of the incidence, types, and risk factors for infections in MCL, informing clinical decisions on prophylaxis and supportive care.

A computational virtual screen of over 2.4 million compounds identified novel covalent BTK inhibitors, providing a foundation for developing next-generation therapeutics for MCL.

This large US prospective cohort study suggests outdoor air pollution is a potential environmental risk factor for developing specific hematologic cancer subtypes, highlighting the importance of subtype-specific etiological research.

This case series on a rare kidney disease (ABBA) reports a paraneoplastic association with mantle cell lymphoma, highlighting a rare non-hematologic manifestation potentially responsive to B-cell directed therapy.

This large Chinese retrospective study of blastoid/pleomorphic MCL links progression of disease within 12 months (POD12) to a distinct mutation profile (TP53, SMARCA4) and poor prognosis.